科兴制药
(688136)
| 流通市值：45.69亿 | | | 总市值：45.69亿 |
| 流通股本：2.02亿 | | | 总股本：2.02亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 607,123,999.5 | 280,525,124.96 | 1,534,028,363.15 | 1,147,639,140.97 |
| 营业收入 | 607,123,999.5 | 280,525,124.96 | 1,534,028,363.15 | 1,147,639,140.97 |
| 二、营业总成本 | 707,017,745.88 | 300,163,833.04 | 1,479,489,096.16 | 1,070,420,698.89 |
| 营业成本 | 278,695,599.85 | 115,997,730.06 | 561,974,212.85 | 418,404,980.55 |
| 税金及附加 | 4,994,325.31 | 2,171,808.01 | 13,429,502.42 | 9,852,036.04 |
| 销售费用 | 242,458,056.08 | 112,836,122.69 | 574,296,480.79 | 420,667,831.17 |
| 管理费用 | 47,631,183.32 | 17,609,997.81 | 93,739,486.77 | 65,714,628.24 |
| 研发费用 | 101,589,619.4 | 34,066,000.91 | 199,553,069.24 | 132,621,448.46 |
| 财务费用 | 31,648,961.92 | 17,482,173.56 | 36,496,344.09 | 23,159,774.43 |
| 其中:利息费用 | 20,889,024.64 | 10,438,289.49 | 41,910,118.44 | 31,019,463.49 |
| 其中:利息收入 | 1,822,106.16 | 803,026.98 | 2,967,897.26 | 2,253,240.28 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 245,632,832.01 | -2,720,308.49 | 79,288,219.78 | 15,439,757.31 |
| 加:投资收益 | 2,170,257.48 | 2,232,766.63 | 29,823,017.46 | 27,187,204.78 |
| 资产处置收益 | 22,729.26 | 4,043 | 954,825.69 | 953,403.74 |
| 资产减值损失(新) | -1,517,706.62 | -3,926,021.5 | -2,342,216.31 | -2,050,530.99 |
| 信用减值损失(新) | -1,022,793 | -2,624,416.03 | -722,973.62 | -5,275,579.45 |
| 其他收益 | 1,191,863.13 | 981,554.1 | 6,570,527.58 | 4,201,064.44 |
| 四、营业利润 | 146,583,435.88 | -25,691,090.37 | 168,110,667.57 | 117,673,761.91 |
| 加:营业外收入 | 721,785.3 | 3,781.38 | 492,636.82 | 488,448.84 |
| 减:营业外支出 | 243,504.78 | 146,787.18 | 2,903,940.9 | 2,823,499.29 |
| 五、利润总额 | 147,061,716.4 | -25,834,096.17 | 165,699,363.49 | 115,338,711.46 |
| 减:所得税费用 | 14,584,468.66 | -7,280,257.7 | 12,955,104.41 | 6,236,575.12 |
| 六、净利润 | 132,477,247.74 | -18,553,838.47 | 152,744,259.08 | 109,102,136.34 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 132,477,247.74 | -18,553,838.47 | 152,744,259.08 | 109,102,136.34 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 133,942,606.03 | -17,936,565.06 | 155,567,752.57 | 111,262,991.17 |
| 少数股东损益 | -1,465,358.29 | -617,273.41 | -2,823,493.49 | -2,160,854.83 |
| 扣除非经常损益后的净利润 | -78,357,407.12 | -18,210,528.32 | 55,832,775.3 | 70,446,588.68 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.68 | -0.09 | 0.79 | 0.56 |
| (二)稀释每股收益 | 0.68 | -0.09 | 0.79 | 0.56 |
| 八、其他综合收益 | -231,677.93 | 263,706.13 | -180,713.14 | -80,087.15 |
| 归属于母公司股东的其他综合收益 | -231,677.93 | 263,706.13 | -180,713.14 | -80,087.15 |
| 九、综合收益总额 | 132,245,569.81 | -18,290,132.34 | 152,563,545.94 | 109,022,049.19 |
| 归属于母公司股东的综合收益总额 | 133,710,928.1 | -17,672,858.93 | 155,387,039.43 | 111,182,904.02 |
| 归属于少数股东的综合收益总额 | -1,465,358.29 | -617,273.41 | -2,823,493.49 | -2,160,854.83 |
| 公告日期 | 2026-08-22 | 2026-04-29 | 2026-04-22 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |